Zelluna promotes Emilie Gauthy to chief technology officer
Norwegian cell therapy developer Zelluna (OSE: ZLNA) has promoted Emilie Gauthy to chief technology officer, effective immediately. Ms Gauthy joined the company in 2022 and has led manufacturing and chemistry, manufacturing and controls work as Zelluna prepares to enter the clinic.
Ms Gauthy will continue to oversee manufacturing and CMC strategy as Zelluna advances its lead program, scales production capacity and expands its off-the-shelf TCR-NK pipeline.
Zelluna said her leadership was central to establishing a scalable manufacturing process that enabled submission of a Clinical Trial Application for ZI-MA4-1 to the UK medicines regulator in December 2025. A GMP clinical batch has been produced and quality tested, with initial clinical data expected from mid-2026.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze